CloneID: F26G3
Antigen Long Description: The original antibody was generated by immunizing BALB/c mice with B. licheniformis γDPGA in combination with CD40 agonist antibody.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Specificity Statement: This antibody specifically binds the poly-γ-D-glutamic acid (γDPGA) capsule of Bacillus anthracis. Bacillus anthracis is surrounded by an antiphagocytic polypeptide capsule composed of poly γ-d-glutamic acid (γDPGA). The γDPGA capsule shields the vegetative form of B. anthracis from agglutination by monoclonal antibodies to its cell wall polysaccharide. γDPGA has been identified recently as a potential target for vaccine development. Bacillus anthracis is a spore-forming bacterium and a causative agent for Anthrax, which is a highly lethal infectious disease in human and poses a great threat as an emerging bioterror agent.
Application Notes (Clone): The binding of this antibody to B. anthracis capsule was assessed by direct immunofluorescence using the Alexa Fluor 488 (Molecular Probes) labeled antibody. An antigen capture ELISA was developed, where this antibody was used as capture antibody and a horseradish peroxidase conjugate of this antibody was used as an indicator antibody. The assessment of assay sensitivity was done using γDPGA from B. licheniformis demonstrated that the assay could detect γDPGA at concentrations as low as 100-140 pg/ml. Passive immunization with this antibody protected >90% of mice in a pulmonary model of anthrax that was lethal in control mice (PMID: 15051894). A 50:50 mixture of PDGA antibodies F24F2 and F26G3 was used in the development of an antigen capture ELISA with a sensitivity of approximately 9 ng/ml of serum after a 1/40 dilution and 2.25 ng/ml for a 1:10 dilution (PMID: 19506008).
Deutsch
English
